PO.CH02.01 · 化学

A proteomic analysis of differential protein expression between platinum-sensitive and platinum-resistant high grade serous ovarian cancer

编号 7683 展板 7 时间 4/22 09:00–12:00 区域 Section 39 主讲 Nujsaubnusi Vue, MD
分会场 Proteomics: Biomarker Discovery and Signaling Networks
该海报暂无可访问的完整资料 AACR 官方页面 ↗

作者与单位

Nujsaubnusi Cassandra Vue1, Kyla Frenia2, Xi Peng3, Eirwen Miller1, John Nakayama1, Sharon Liang1, Sarah Crafton1, Alyssa Wield1, Christopher Morse1, Thomas Krivak1, Qiangmin Zheng3, Kunhong Xiao3

1Western Pennsylvania Hospital, Pittsburgh, PA,2University of Pittsburgh, Pittsburgh, PA,3Allegheny Health Network, Pittsburgh, PA

摘要 Abstract

Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Platinum-based therapy is the mainstay of treatment, with 70% chance of treatment sensitivity. Resistance to platinum therapy is the leading cause of mortality in advanced ovarian cancer. There are limited studies using proteomics to evaluate platinum resistance in ovarian cancer. This study aims to perform proteomic evaluation of treatment naive tissue from high grade serous ovarian cancer (HGSOC) tumors that are platinum-sensitive (PS) versus resistant (PR). Methods: Formalin-fixed paraffin-embedded (FFPE) tumor tissue collected from 63 patients with HGSOC were analyzed, including 40 PS & 23 PR. Platinum sensitivity was defined as disease response without evidence of recurrence after 6 months of treatment. Samples were analyzed using a high-throughput liquid chromatography-tandem mass spectrometry (LC-MS/MS) protocol. Differential expression (DE) analysis was performed to identify proteins distinguishing between the two groups. Unsupervised machine learning techniques such as least absolute shrinkage and selection operator (LASSO) regression analysis, linear discriminant analysis (LDA), and weighted gene co-expression network analysis (WCGNA) were employed to create a differentially expressed protein profile between PS and PR. Results: Among 4048 proteins identified, 1,604 met quality thresholds for further analysis, appearing in >50% of samples. Thirty-seven proteins were significantly differentially expressed with four upregulated in PS and 33 upregulated in PR. With LASSO regression analysis, an additional 61 DE proteins were identified. LDA revealed 7 proteins (DPM1, INF2, ISYNA1, RBM12B, ATP5F1C, GNL1, UBA7) to have a predictive potential with 85% sensitivity and 100% specificity. Functional enrichment analysis implicated pathways related to RNA binding, epigenetic regulation, spliceosome activity, glutathione metabolism, and metabolic reprogramming in platinum sensitivity. Conclusion: With the combination of traditional statistics and unsupervised machine learning, this study generated a list of DE proteins and facilitated a 7-protein panel that can be used to further investigate and understand the complex tumor dynamics behind platinum sensitivity and resistance.
利益披露 Disclosure
N. C. Vue, None.. K. Frenia, None.. X. Peng, None.. E. Miller, None. J. Nakayama, AstraZeneca Other, consulting fees and payment. Abbvie Other, consulting fees. Myriad Other, consulting fees and payment. Merck Other, Payment. Eisai Payment. S. Liang, None. S. Crafton, Pfizer g., Board of Directors, non-salaried role), consulting or advisory board. Karyopharm g., Board of Directors, non-salaried role), consulting or advisory board. GSK g., Board of Directors, non-salaried role), consulting or advisory board. Medtronic g., Board of Directors, non-salaried role), consulting or advisory board. A. Wield, None. C. Morse, MJH Lifesciences Honoraria. Topline Bio Honoraria. T. Krivak, Astra Zeneca Other, consulting fees, payments, and honoraria. Immunogen Other, consulting fees, payments, and honoraria. GSK Other, consulting fees, payments, and honoraria. Myriad Other, consulting fees, payments, and honoraria. Q. Zheng, None.. K. Xiao, None.

在会议检索中打开